GLP1R and type 2 diabetes mellitus: The long-term effects of SGLT2i on the risk of new onset CKD were evaluated in a primary care real-world setting in patients with T2DM, observing that these drugs reduced the incidence of new onset CKD as did GLP1-RA [115], supporting the feasibility of primary prevention of CKD in the primary care setting by prescribing glucose-lowering drugs fit for this purpose.